| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | ANIP | Common Stock | Award | +13.5K | 13.5K | Nov 19, 2021 | Direct | F1 | |||
| transaction | ANIP | Common Stock | Award | +1.33M | 1.33M | Nov 19, 2021 | Held by Esjay LLC | F2, F3 |
| Id | Content |
|---|---|
| F1 | On November 19, 2021, pursuant to that certain Agreement and Plan of Merger, dated as of March 8, 2021 (as amended, supplemented or modified from time to time, the "Merger Agreement"), by and among ANI Pharmaceuticals, Inc., a Delaware corporation (the "Issuer"), Novitium Pharma LLC, a Delaware limited liability company ("Novitium"), and the other parties thereto, the Issuer completed its acquisition of Novitium. In accordance with the Merger Agreement, an aggregate of 70,250 Company Interests of Novitium held by the Reporting Person were converted into 13,460 shares of Common Stock of the Issuer. The issuance of the shares was approved by the Issuer's board of directors pursuant to Rule 16b-3 under the Securities Exchange Act of 1934, as amended. |
| F2 | In accordance with the Merger Agreement, an aggregate of 6,954,750 Company Interests of Novitium held by Esjay LLC were converted into 1,332,620 shares of Common Stock of the Issuer. The issuance of the shares was approved by the Issuer's board of directors pursuant to Rule 16b-3 under the Securities Exchange Act of 1934, as amended. |
| F3 | The Reporting Person holds voting and dispositive power over the shares held by Esjay LLC. |